Pharming Group (ENXTAM:PHARM) Stock Faces Q3 Earnings Valuation Reckoning

Pharming Group stock closed at €1.08 on 27 October after a choppy few months, just as fresh Q3 2026 numbers landed. Traders focused on the recent volatility. Long term holders are staring at something different. The quarter delivered revenue of US$117.6m and net income of US$22.4m, which sharply lifted reported earnings per share.

In the short term, the question is whether that jump justifies a rich P/E multiple in a volatile rare disease biotech. Over a multi year lens, the bigger story is an improving profit margin set against premium valuation and a pipeline that will need to keep earning that price tag.

Love Pharming Group’s jump in earnings but worried about paying up for a volatile rare disease player with a rich P/E? Benchmark it against a curated group of financially stronger stocks in our list of solid balance sheet and fundamentals stocks (207 results)

Q3 2026 Earnings Summary

• Revenue (Q3 2026 vs Q3 2025): US$117.6m vs. US$97.3m (up roughly 21%)
• Net Income (Q3 2026 vs Q3 2025): US$22.4m vs. US$7.5m (up about 3x)
• Basic EPS (Q3 2026 vs Q3 2025): US$0.0328 vs. US$0.0150 (more than 2x higher)
• Net Profit Margin (TTM to Q3 2026 vs prior year TTM): 6.3% vs. 0.1% (moved from roughly breakeven to the mid single-digit range)

Prefer clean visuals instead of another dense block of Pharming Group figures and footnotes? Get a full chart-driven view of the business, with its valuation front and center, in the company report for Pharming Group.

Pharming bull case: rare disease platform thesis on trial

The optimistic story says Pharming Group is shifting from a niche APDS play to a broader rare disease platform built around multiple assets rather than a single drug.

"Bullish analysts expect Pharming Group to transition from a single-asset story into a broader rare disease platform built around RUCONEST, Joenja and leniolisib as the company advances into larger primary immunodeficiency segments."

Q3 shows parts of that script playing out. Joenja revenue reached US$23.8m with new launches in Germany and Japan, plus fresh U.S. pediatric dosing. Leniolisib Phase II data in immune dysregulation primary immunodeficiencies hit the bar for organ and lung markers, and all completers moved into the 3 year extension. Cash and securities of US$190.9m and trimmed opex guidance support the claim that the platform build is funded for now.

Pharming bear case: RUCONEST reliance and execution risk tested

The sceptical view focuses on RUCONEST dependence and the possibility that heavy spending and competitive pressure blunt the pay off from the pipeline.

"The earlier concern that RUCONEST might be squeezed in a narrow severe HAE niche is still live, since Pharming Group lowered full year 2026 revenue guidance by US$30 million and highlighted ongoing competitive pressure from new oral on demand therapies."

Q3 RUCONEST revenue of US$93.8m, with 14% year on year growth and strong patient retention, challenges the idea of rapid erosion. Yet management tightened 2026 revenue guidance to US$380m to US$390m and cut opex plans after earlier reductions, which underlines that pricing and volume pressure, along with R&D and restructuring spend, are still weighing on visibility.

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for.

Hunt For Mispriced Earnings Power

Pharming Group’s latest quarter shows how quickly a narrative can pivot when margins and guidance move in the same direction. The real opportunity could be spotting stocks that look mispriced before the market closes that gap.

• Company 1 - 41% below our estimate - targets higher margin protective films and services as new manufacturing capacity reshapes supply and dealer relationships across key auto channels.
• Company 2 - 27% below our estimate - embeds networking, custom silicon and software at choke points where rising data traffic must be processed, moved, secured and managed for critical enterprise workloads.
• Company 3 - 45% below our estimate - expands AI focused power and rack solutions so large cloud providers can address capacity bottlenecks and plan new data center projects across multiple sites.

That is three of the list. See the full list of 195 companies trading below our fair value estimates →

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com